Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
American Journal of Cardiovascular Drugs
Erschienen in: American Journal of Cardiovascular Drugs 3/2012

01.06.2012 | Review Article

Role of Antihypertensive Drugs in Arterial ‘De-Stiffening’ and Central Pulsatile Hemodynamics

verfasst von: Charalambos Koumaras, Maria Tzimou, Eirini Stavrinou, Theodora Griva, Thomas D. Gossios, Niki Katsiki, Vasilios G. Athyros, Dr Dimitri P. Mikhailidis, Asterios Karagiannis

Erschienen in: American Journal of Cardiovascular Drugs | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Arterial stiffness is an independent predictor of cardiovascular (CV) morbidity and mortality in patients with hypertension, as well as a potential therapeutic target. There is increasing awareness that the pulsatile hemodynamics (central blood pressure [CBP], pulse pressure [PP], wave reflections [augmentation index or AIx] and pulse wave velocity [PWV]) may provide better insight into the pathophysiology of CV disorders and target organ damage related to hypertension. Different antihypertensive drugs produce diverse effects on arterial stiffness variables, despite similar effects on peripheral (brachial) blood pressure. Identifying the pharmacologic interventions that can improve arterial stiffness (‘de-stiffening’ treatment) is a promising field of research.
Literatur
1.
Laurent S, Cockcroft J, Van Bortel L, et al. European Network for Noninvasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006 Nov; 27(21): 2588–605
2.
McEniery CM, Yasmin, McDonnell B, et al. Anglo-Cardiff Collaborative Trial Investigators. Central pressure: variability and impact of cardiovascular risk factors: the Anglo-Cardiff Collaborative Trial II. Hypertension 2008 Jun; 51(6): 1476–82
3.
Tziomalos K, Athyros VG, Karagiannis A, et al. Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management. Nutr Metab Cardiovasc Dis 2010 Feb; 20(2): 140–6PubMedCrossRef
4.
Goch A, Banach M, Mikhailidis DP, et al. Endothelial dysfunction in patients with non complicated and complicated hypertension. Clin Exp Hypertens 2009 Feb; 31(1): 20–30PubMedCrossRef
5.
Tziomalos K, Athyros VG, Karagiannis A, et al. Endothelial function, arterial stiffness and lipid lowering drugs. Expert Opin Ther Targets 2007 Sep; 11(9): 1143–60PubMedCrossRef
6.
7.
Rossi P, Francès Y, Kingwell BA, et al. Gender differences in artery wall biomechanical properties throughout life. J Hypertens 2011 Jun; 29(6): 1023–33PubMedCrossRef
8.
McEniery CM, Wilkinson IB, Avolio AP. Age, hypertension and arterial function. Clin Exp Pharmacol Physiol 2007 Jul; 34(7): 665–71PubMedCrossRef
9.
Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia 2008 Apr; 51(4): 527–39PubMedCrossRef
10.
Seifalian AM, Filippatos TD, Joshi J, et al. Obesity and arterial compliance alterations. Curr Vasc Pharmacol 2010 Mar; 8(2): 155–68PubMedCrossRef
11.
Doonan RJ, Hausvater A, Scallan C, et al. The effect of smoking on arterial stiffness. Hypertens Res 2010 May; 33(5): 398–410PubMedCrossRef
12.
Black HR. The paradigm has shifted, to systolic blood pressure. Hypertension 1999 Sep; 34(3): 386–7PubMedCrossRef
13.
Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease: the Framingham study. Am J Cardiol 1971 Apr; 27(4): 335–46PubMedCrossRef
14.
Jankowski P, Kawecka-Jaszcz K, Czarnecka D, et al., Aortic Blood Pressure and Survival Study Group. Pulsatile but not steady component of blood pressure predicts cardiovascular events in coronary patients. Hypertension 2008 Apr; 51(4): 848–55PubMedCrossRef
15.
Roman MJ, Devereux RB, Kizer JR, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension 2007 Jul; 50(1): 197–203PubMedCrossRef
16.
Agabiti-Rosei E, Mancia G, O’Rourke MF, et al. Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension 2007 Jul; 50(1): 154–60PubMedCrossRef
17.
Katsiki N, Koumaras C, Athyros VG, et al. Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk. Angiology 2012 Jan; 63(1): 9–11PubMedCrossRef
18.
Laurent S, Katsahian S, Fassot C, et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003 May; 34(5): 1203–6PubMedCrossRef
19.
Mitchell GF, Hwang SJ, Vasan RS, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation 2010 Feb; 121(4): 505–11PubMedCrossRef
20.
Morgan T, Lauri J, Bertram D, et al. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004 Feb; 17(2): 118–23PubMedCrossRef
21.
Tropeano AI, Boutouyrie P, Pannier B, et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 2006 Jul; 48(1): 80–6PubMedCrossRef
22.
Conway J, Lauwers P. Hemodynamic and hypotensive effects of long-term therapy with chlorothiazide. Circulation 1960 Jan; 21: 21–7PubMedCrossRef
23.
Dhakam Z, Yasmin, McEniery CM, et al. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008 Feb; 26(2): 351–6PubMedCrossRef
24.
Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003; 19(6): 540–56PubMedCrossRef
25.
Kontopoulos AG, Athyros VG, Pehlivanidis AN, et al. Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients. Curr Med Res Opin 2003; 19(1): 22–7PubMedCrossRef
26.
Agarwal N, Rice SP, Bolusani H, et al. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab 2010 Feb; 95(2): 722–30PubMedCrossRef
27.
Harashima K, Hayashi J, Miwa T, et al. Long-term pioglitazone therapy improves arterial stiffness in patients with type 2 diabetes mellitus. Metabolism 2009 Jun; 58(6): 739–45PubMedCrossRef
28.
Tanaka H, Munakata M, Kawano Y, et al. Comparison between carotidfemoral and brachial-ankle pulse wave velocity as measures of arterial stiffness. J Hypertens 2009 Oct; 27(10): 2022–7PubMedCrossRef
29.
Tsuchikura S, Shoji T, Kimoto E, et al. Brachial-ankle pulse wave velocity as an index of central arterial stiffness. J Atheroscler Thromb 2010 Jun; 17(6): 658–65PubMedCrossRef
30.
Hongo M, Kumazaki S, Izawa A, et al. Low-dose rosuvastatin improves arterial stiffness in high-risk Japanese patients with dyslipdemia in a primary prevention group. Circ J 2011 Oct; 75(11): 2660–7PubMedCrossRef
31.
Shirai K, Hiruta N, Song M, et al. Cardio-ankle vascular index (CAVI) as a novel indicator of arterial stiffness: theory, evidence and perspectives. J Atheroscler Thromb 2011; 18(11): 924–38PubMedCrossRef
32.
Dolan E, Li Y, Thijs L, et al. Ambulatory arterial stiffness index: rationale and methodology. Blood Press Monit 2006 Apr; 11(2): 103–5PubMedCrossRef
33.
Van Bortel LM, Struijker-Boudier HA, Safar ME. Pulse pressure, arterial stiffness, and drug treatment of hypertension. Hypertension 2001 Oct; 38(4): 914–21PubMedCrossRef
34.
Safar ME, Jankowski P. Antihypertensive therapy and de-stiffening of the arteries. Expert Opin Pharmacother 2010 Nov; 11(16): 2625–34PubMedCrossRef
35.
Mahmud A, Feely J. Arterial stiffness and the renin-angiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst 2004 Sep; 5(3): 102–8PubMedCrossRef
36.
Protogerou AD, Papaioannou TG, Lekakis JP, et al. The effect of antihypertensive drugs on central blood pressure beyond peripheral blood pressure. Part I: (Patho)-physiology, rationale and perspective on pulse pressure amplification. Curr Pharm Des 2009; 15(3): 267–71
37.
van der Heijden-Spek JJ, Staessen JA, Fagard RH, et al. Effect of age on brachial artery wall properties differs from the aorta and is gender dependent: a population study. Hypertension 2000 Feb; 35(2): 637–42PubMedCrossRef
38.
Kool MJ, Spek JJ, Struyker Boudier HA, et al. Acute and subacute effects of nicorandil and isosorbide dinitrate on vessel wall properties of large arteries and hemodynamics in healthy volunteers. Cardiovasc Drugs Ther 1995 Apr; 9(2): 331–7PubMedCrossRef
39.
Laurent S, Arcaro G, Benetos A, et al. Mechanism of nitrate-induced improvement on arterial compliance depends on vascular territory. J Cardiovasc Pharmacol 1992 Apr; 19(4): 641–9PubMedCrossRef
40.
Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003 Jun; 107(22): 2864–9PubMedCrossRef
41.
Mitchell GF, Lacourcière Y, Arnold JM, et al. Changes in aortic stiffness and augmentation index after acute converting enzyme or vasopeptidase inhibition. Hypertension 2005 Nov; 46(5): 1111–7PubMedCrossRef
42.
Avolio AP, Van Bortel LM, Boutouyrie P, et al. Role of pulse pressure amplification in arterial hypertension: experts’ opinion and review of the data. Hypertension 2009 Aug; 54(2): 375–83PubMedCrossRef
43.
Ahimastos AA, Natoli AK, Lawler A, et al. Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertension 2005 Jun; 45(6): 1194–9PubMedCrossRef
44.
Wilkinson IB, McEniery CM. Arterial stiffness, endothelial function and novel pharmacological approaches. Clin Exp Pharmacol Physiol 2004 Nov; 31(11): 795–9PubMedCrossRef
45.
Bakris GL, Bank AJ, Kass DA, et al. Advanced glycation end-product crosslink breakers: a novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens 2004 Dec; 17(12 Pt 2): 23S–30SPubMedCrossRef
46.
Shapiro BP, Owan TE, Mohammed SF, et al. Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines. Circulation 2008 Sep; 118(10): 1002–10PubMedCrossRef
47.
Kass DA, Shapiro EP, Kawaguchi M, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001 Sep; 104(13): 1464–70PubMedCrossRef
48.
Avolio AP, Deng FQ, Li WQ, et al. Effects of aging on arterial distensibility in populations with high and low prevalence of hypertension: comparison between urban and rural communities in China. Circulation 1985 Feb; 71(2): 202–10PubMedCrossRef
49.
Safar ME. Can antihypertensive treatment reverse large-artery stiffening?. Curr Hypertens Rep 2010 Feb; 12(1): 47–51PubMedCrossRef
50.
Dao HH, Essalihi R, Bouvet C, et al. Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension. Cardiovasc Res 2005 May; 66(2): 307–17PubMedCrossRef
51.
Kakou A, Bézie Y, Mercier N, et al. Selective reduction of central pulse pressure under angiotensin blockage in SHR: role of the fibronectin-alpha5beta1 integrin complex. Am J Hypertens 2009 Jul; 22(7): 711–7PubMedCrossRef
52.
Louis H, Kakou A, Regnault V, et al. Role of alpha1beta1-integrin in arterial stiffness and angiotensin-induced arterial wall hypertrophy in mice. Am J Physiol Heart Circ Physiol. 2007 Oct; 293(4): H2597–604PubMedCrossRef
53.
Bézie Y, Lamazière JM, Laurent S, et al. Fibronectin expression and aortic wall elastic modulus in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1998 Jul; 18(7): 1027–34PubMedCrossRef
54.
Labat C, Lacolley P, Lajemi M, et al. Effects of valsartan on mechanical properties of the carotid artery in spontaneously hypertensive rats under high-salt diet. Hypertension 2001 Sep; 38(3): 439–43PubMedCrossRef
55.
Jankowski P, Safar ME, Benetos A. Pleiotropic effects of drugs inhibiting the renin-angiotensin-aldosterone system. Curr Pharm Des 2009; 15(5): 571–84PubMedCrossRef
56.
Protogerou AD, Stergiou GS, Vlachopoulos C, et al. The effect of antihypertensive drugs on central blood pressure beyond peripheral blood pressure. Part II: Evidence for specific class-effects of antihypertensive drugs on pressure amplification. Curr Pharm Des 2009; 15(3): 272–89
57.
Ghiadoni L, Virdis A, Magagna A, et al. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 2000 Jan; 35(1 Pt 2): 501–6PubMedCrossRef
58.
Hornig B, Landmesser U, Kohler C, et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001 Feb; 103(6): 799–805PubMedCrossRef
59.
Richer C, Bruneval P, Ménard J, et al. Additive effects of enalapril and losartan in (mREN-2)27 transgenic rats. Hypertension 1998 Feb; 31(2): 692–8PubMedCrossRef
60.
Jorde UP, Ennezat PV, Lisker J, et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000 Feb; 101(8): 844–6PubMedCrossRef
61.
Schmidt BM, Schmieder RE. Aldosterone-induced cardiac damage: focus on blood pressure independent effects. Am J Hypertens 2003 Jan; 16(1): 80–6PubMedCrossRef
62.
Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000 Nov; 102(22): 2700–6CrossRef
63.
Lacolley P, Labat C, Pujol A, et al. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation 2002 Nov; 106(22): 2848–53PubMedCrossRef
64.
Jiang XJ, OśRourke MF, Jin WQ, et al. Quantification of glyceryl trinitrate effect through analysis of the synthesised ascending aortic pressure waveform. Heart 2002 Aug; 88(2): 143–8PubMedCrossRef
65.
Gori T, Parker JD. Nitrate tolerance: a unifying hypothesis. Circulation 2002 Nov; 106(19): 2510–3PubMedCrossRef
66.
London GM, Asmar RG, OśRourke MF, et al. REASON Project Investigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004 Jan; 43(1): 92–9
67.
Karagiannis A, Mikhailidis DP, Kakafika AI, et al. Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome? Curr Pharm Des 2007; 13(2): 229–39PubMedCrossRef
68.
Williams B, Lacy PS, Thom SM, et al., CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressurelowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006 Mar; 113(9): 1213–25PubMedCrossRef
69.
Chen CH, Ting CT, Lin SJ, et al. Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension 1995 May; 25(5): 1034–41PubMedCrossRef
70.
Dhakam Z, McEniery CM, Yasmin, et al. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens 2006 Feb; 19(2): 214–9PubMedCrossRef
71.
Mackenzie IS, McEniery CM, Dhakam Z, et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009 Aug; 54(2): 409–13PubMedCrossRef
72.
Mahmud A, Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens 2008 Jun; 21(6): 663–7PubMedCrossRef
73.
McEniery CM, Schmitt M, Qasem A, et al. Nebivolol increases arterial distensibility in vivo. Hypertension 2004 Sep; 44(3): 305–10PubMedCrossRef
74.
Polónia J, Barbosa L, Silva JA, et al. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with b-blockers either with or without vasodilator properties or with angiotensin receptor blockers. Blood Press Monit 2010 Oct; 15(5): 235–9PubMedCrossRef
75.
Agabiti-Rosei E, Porteri E, Rizzoni D. Arterial stiffness, hypertension, and rational use of nebivolol. Vasc Health Risk Manag 2009; 5(1): 353–60PubMedCrossRef
76.
Karagiannis A, Athyros VG, Papageorgiou A, et al. Should atenolol still be recommended as first-line therapy for primary hypertension?. Hellenic J Cardiol 2006 Sep–Oct; 47(5): 298–307PubMed
77.
Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005 Oct–Nov; 366(9496): 1545–53PubMedCrossRef
78.
Pedersen ME, Cockcroft JR. What is the role, if any, for beta-blockers as initial therapy for uncomplicated hypertension? Curr Opin Cardiol 2009 Jul; 24(4): 325–32PubMedCrossRef
79.
Jiang XJ, OśRourke MF, Zhang YQ, et al. Superior effect of an angiotensinconverting enzyme inhibitor over a diuretic for reducing aortic systolic pressure. J Hypertens 2007 May; 25(5): 1095–9PubMedCrossRef
80.
Dart AM, Cameron JD, Gatzka CD, et al. Similar effects of treatment on central and brachial blood pressures in older hypertensive subjects in the Second Australian National Blood Pressure Trial. Hypertension 2007 Jun; 49(6): 1242–7PubMedCrossRef
81.
Ting CT, Chen CH, Chang MS, et al. Short- and long-term effects of antihypertensive drugs on arterial reflections, compliance, and impedance. Hypertension 1995 Sep; 26(3): 524–30PubMedCrossRef
82.
Topouchian J, Brisac AM, Pannier B, et al. Assessment of the acute arterial effects of converting enzyme inhibition in essential hypertension: a doubleblind, comparative and crossover study. J Hum Hypertens 1998 Mar; 12(3): 181–7PubMedCrossRef
83.
de Luca N, Asmar RG, London GM, et al., REASON Project Investigators. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. J Hypertens 2004 Aug; 22(8): 1623–30PubMedCrossRef
84.
Kengne AP, Czernichow S, Huxley R, et al., ADVANCE Collaborative Group. Blood pressure variables and cardiovascular risk: new findings from ADVANCE. Hypertension 2009 Aug; 54(2): 399–404PubMedCrossRef
85.
Dahlöf B, Sever PS, Poulter NR, et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 Sep; 366(9489): 895–906PubMedCrossRef
86.
Mitchell GF, Dunlap ME, Warnica W, et al., Prevention of Events With Angiotensin-Converting Enzyme Inhibition Investigators. Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy. Hypertension 2007 Jun; 49(6): 1271–7PubMedCrossRef
87.
Wing LM, Reid CM, Ryan P, et al., Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensinconverting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003 Feb; 348(7): 583–92PubMedCrossRef
88.
Stokes GS, Barin ES, Gilfillan KL. Effects of isosorbide mononitrate and AII inhibition on pulse wave reflection in hypertension. Hypertension 2003 Feb; 41(2): 297–301PubMedCrossRef
89.
Aznaouridis KA, Stamatelopoulos KS, Karatzis EN, et al. Acute effects of renin-angiotensin system blockade on arterial function in hypertensive patients. J Hum Hypertens 2007 Aug; 21(8): 654–63PubMedCrossRef
90.
London GM, Pannier B, Guerin AP, et al. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994 Dec; 90(6): 2786–96
91.
Lacourcière Y, Béliveau R, Conter HS, et al., Canadian Hypertension Society. Effects of perindopril on elastic and structural properties of large arteries in essential hypertension. Can J Cardiol 2004 Jun; 20(8): 795–9PubMed
92.
Pannier BM, Guerin AP, Marchais SJ, et al. Different aortic reflection wave responses following long-term angiotensin-converting enzyme inhibition and beta-blocker in essential hypertension. Clin Exp Pharmacol Physiol 2001 Dec; 28(12): 1074–7PubMedCrossRef
93.
Rehman A, Ismail SB, Naing L, et al. Reduction in arterial stiffness with angiotensin II antagonism and converting enzyme inhibition: a comparative study among Malay hypertensive subjects with a known genetic profile. Am J Hypertens 2007 Feb; 20(2): 184–9PubMedCrossRef
94.
Topouchian J, Asmar R, Sayegh F, et al. Changes in arterial structure and function under trandolapril-verapamil combination in hypertension. Stroke 1999 May; 30(5): 1056–64PubMedCrossRef
95.
Kaiser T, Heise T, Nosek L, et al. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens 2006 Jul; 24(7): 1397–403PubMedCrossRef
96.
Deary AJ, Schumann AL, Murfet H, et al. Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. Clin Sci 2002 Nov; 103(5): 493–9PubMedCrossRef
97.
Ali K, Rajkumar C, Fantin F, et al. Irbesartan improves arterial compliance more than lisinopril. Vasc Health Risk Manag 2009; 5(4): 587–92PubMedCrossRef
98.
Hirata K, Vlachopoulos C, Adji A, et al. Benefits from angiotensin-converting enzyme inhibitor ‘beyond blood pressure lowering’: beyond blood pressure or beyond the brachial artery?. J Hypertens 2005 Mar; 23(3): 551–6PubMedCrossRef
99.
London GM, Pannier B, Vicaut E, et al. Antihypertensive effects and arterial haemodynamic alterations during angiotensin converting enzyme inhibition. J Hypertens 1996 Sep; 14(9): 1139–46PubMedCrossRef
100.
Ferguson JM, Minas J, Siapantas S, et al. Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension. J Cardiovasc Pharmacol 2008 Jun; 51(6): 590–5PubMedCrossRef
101.
Mahmud A, Feely J. Favourable effects on arterial wave reflection and pulse pressure amplification of adding angiotensin II receptor blockade in resistant hypertension. J Hum Hypertens 2000 Sep; 14(9): 541–6PubMedCrossRef
102.
Mahmud A, Feely J. Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. Am J Hypertens 2002 Apr; 15(4 Pt 1): 321–5PubMedCrossRef
103.
Klingbeil AU, John S, Schneider MP, et al. AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study. J Hypertens 2002 Dec; 20(12): 2423–8PubMedCrossRef
104.
Karalliedde J, Smith A, DeAngelis L, et al. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension 2008 Jun; 51(6): 1617–23PubMedCrossRef
105.
Kosch M, Levers A, Lang D, et al. A randomized, double-blind study of valsartan versus metoprolol on arterial distensibility and endothelial function in essential hypertension. Nephrol Dial Transplant 2008 Jul; 23(7): 2280–5PubMedCrossRef
106.
Mediavilla García JD, Fernández-Torres C, Jaén Aguila F, et al. Effect of olmesartan medoxomil on arterial stiffness in patients with essential hypertension. Med Clin (Barc) 2007 May; 128(19): 726–9CrossRef
107.
Matsui Y, Eguchi K, OśRourke MF, et al. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 2009 Oct; 54(4): 716–23PubMedCrossRef
108.
Asmar R. Effect of telmisartan on arterial distensibility and central blood pressure in patients with mild to moderate hypertension and type 2 diabetes mellitus. J Renin Angiotensin Aldosterone Syst 2001 Sep; 2 Suppl. 2: S8–11PubMedCrossRef
109.
Jung AD, Kim W, Park SH, et al. The effect of telmisartan on endothelial function and arterial stiffness in patients with essential hypertension. Korean Circ J 2009 May; 39(5): 180–4PubMedCrossRef
110.
Mahmud A, Feely J. Effect of angiotensin II receptor blockade on arterial stiffness: beyond blood pressure reduction. Am J Hypertens 2002 Dec; 15(12): 1092–5PubMedCrossRef
111.
Davies J, Carr E, Band M, et al. Do losartan and atenolol have differential effects on BNP and central haemodynamic parameters?. J Renin Angiotensin Aldosterone Syst 2005 Dec; 6(3): 151–3PubMedCrossRef
112.
Dahlöf B, Devereux RB, Kjeldsen SE, et al., LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar; 359(9311): 995–1003PubMedCrossRef
113.
Julius S, Kjeldsen SE, Weber M, et al., VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004 Jun; 363(9426): 2022–31PubMedCrossRef
114.
Julius S, Weber MA, Kjeldsen SE, et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006 Sep; 48(3): 385–91PubMedCrossRef
115.
Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTI-MAAL Study Group Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002 Sep; 360(9335): 752–60
116.
Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens 2005 Jan; 18(1): 50–5PubMedCrossRef
117.
Kithas PA, Supiano MA. Spironolactone and hydrochlorothiazide decrease vascular stiffness and blood pressure in geriatric hypertension. J Am Geriatr Soc 2010 Jul; 58(7): 1327–32PubMedCrossRef
118.
Edwards NC, Steeds RP, Stewart PM, et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 2009 Aug; 54(6): 505–12PubMedCrossRef
119.
White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003 May; 41(5): 1021–6PubMedCrossRef
120.
Savoia C, Touyz RM, Amiri F, et al. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 2008 Feb; 51(2): 432–9PubMedCrossRef
121.
Cherney DZ, Lai V, Scholey JW, et al. Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes: a pilot study. Diabetes Care 2010 Feb; 33(2): 361–5PubMedCrossRef
122.
Palombo C, Malshi E, Morizzo C, et al. Arterial wave reflection during antihypertensive therapy with barnidipine: a 6-month, open-label study using an integrated cardiovascular ultrasound approach in patients with newly diagnosed hypertension. Clin Ther 2009 Dec; 31(12): 2873–85PubMedCrossRef
123.
Alem M, Milia P, Muir S, et al. Comparison of the effects of diuretics on blood pressure and arterial stiffness in patients with stroke. J Stroke Cerebrovasc Dis 2008 Nov–Dec; 17(6): 373–7PubMedCrossRef
124.
Lekakis JP, Protogerou A, Papamichael C, et al. Effect of nebivolol and atenolol on brachial artery flow-mediated vasodilation in patients with coronary artery disease. Cardiovasc Drugs Ther 2005 Aug; 19(4): 277–81PubMedCrossRef
125.
Heffernan KS, Suryadevara R, Patvardhan EA, et al. Effect of atenolol vs metoprolol succinate on vascular function in patients with hypertension. Clin Cardiol 2011 Jan; 34(1): 39–44PubMedCrossRef
126.
The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 guidelines for the management of arterial hypertension. Eur Heart J. 2007 Jun; 28(12): 1462–536PubMed
127.
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009 Nov; 27 (11): 2121–58
128.
Kelly RP, Gibbs HH, OśRourke MF, et al. Nitroglycerin has more favourable effects on left ventricular afterload than apparent from measurement of pressure in a peripheral artery. Eur Heart J 1990 Feb; 11(2): 138–44PubMed
129.
Simkus GJ, Fitchett DH. Radial arterial pressure measurements may be a poor guide to the beneficial effects of nitroprusside on left ventricular systolic pressure in congestive heart failure. Am J Cardiol 1990 Aug; 66(3): 323–6PubMedCrossRef
130.
Ong KT, Delerme S, Pannier B, et al. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients. J Hypertens 2011 Jun; 29(6): 1034–42PubMedCrossRef
131.
Van Bortel LM, De Backer T, De Buyzere M. How to treat arterial stiffness beyond blood pressure lowering?. J Hypertens 2011 Jun; 29(6): 1051–3PubMedCrossRef
Metadaten
Titel
Role of Antihypertensive Drugs in Arterial ‘De-Stiffening’ and Central Pulsatile Hemodynamics
verfasst von
Charalambos Koumaras
Maria Tzimou
Eirini Stavrinou
Theodora Griva
Thomas D. Gossios
Niki Katsiki
Vasilios G. Athyros
Dr Dimitri P. Mikhailidis
Asterios Karagiannis
Publikationsdatum
01.06.2012
Verlag
Springer International Publishing
Erschienen in
American Journal of Cardiovascular Drugs / Ausgabe 3/2012
Print ISSN: 1175-3277
Elektronische ISSN: 1179-187X
DOI
https://doi.org/10.2165/11599040-000000000-00000

Weitere Artikel der Ausgabe 3/2012

American Journal of Cardiovascular Drugs 3/2012 Zur Ausgabe

Review Article

Therapeutic Potential of Terminalia Arjuna in Cardiovascular Disorders

Original Research Article

Consistency of Extended-Release Niacin/Laropiprant Effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 Ratio Across Patient Subgroups

Original Research Article

Comparison of the Efficacy and Safety of Fixed-Dose Amlodipine/Losartan and Losartan in Hypertensive Patients Inadequately Controlled with Losartan

Adis Drug Clinical Q&A

Prasugrel: A Guide to Its Use in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention in the US

Original Research Article

Heart Rate-Lowering Efficacy and Respiratory Safety of Ivabradine in Patients with Obstructive Airway Disease

Review Article

Epidemiology and Management of Hypertension in the Hispanic Population

Neu im Fachgebiet Kardiologie

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

LDL-Cholesterin kann ApoB als Risikomarker nicht ersetzen

16.05.2024 Hypercholesterinämie Nachrichten

Apolipoprotein B (ApoB) ist ein genauer Risikomarker für atherosklerotisch bedingte Erkrankungen. Aber das LDL-Cholesterin doch auch – lohnt sich also die ApoB-Messung überhaupt?

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise